Literature DB >> 12063010

Preservation of parotid function with uncomplicated conformal radiotherapy.

Annelies Maes1, Caroline Weltens, Patrick Flamen, Philippe Lambin, Ria Bogaerts, Xuan Liu, Jan Baetens, Robert Hermans, Walter Van den Bogaert.   

Abstract

BACKGROUND AND
PURPOSE: To evaluate (1) parotid function, (2) subjective xerostomia and (3) pattern of relapses after conformal parotid-sparing radiotherapy (RT) for head and neck cancer. (4) To study dose-response curves of parotid glands.
MATERIAL AND METHODS: From September 1999 to November 2000, 39 head and neck cancer patients requiring bilateral neck RT were treated with a fairly simple conformal RT technique (three-field set-up+anterior lower neck field; two opposed oblique boost fields). The contralateral parotid was spared. Parotid function was assessed by salivary gland scintigraphies performed before, early (median 4 weeks) and late (median 28 weeks) after RT. Xerostomia was monitored by visual analogue scales (VAS) and LENT SOMA scores. Location of locoregional recurrences was studied in relation to the radiation fields. A dose-response curve of parotids was created using logistic regression.
RESULTS: (1) Early after RT, on salivary gland scintigraphy, the mean loss of secretion function in the spared parotid was 67% and total in the non-spared. Late after RT, the mean loss remained 19% in the spared and total in the non-spared parotid. Normal excretion function was regained in 75% of the spared parotids. (2) Late after RT, 78% of patients had no, minimal or acceptable subjective xerostomia. (3) No recurrence was seen near the spared parotid (11/39 locoregional recurrences). (4) The dose-response curve of parotids showed that the mean parotid dose should preferentially be < or =20 Gy, to obtain a good chance (> or =70%) for preservation of its function on scintigraphy.
CONCLUSIONS: An easy conformal parotid-sparing RT technique prevents moderate or severe subjective xerostomia in 78% of patients. In the spared parotids, nearly complete to complete recovery is obtained after 6-12 months.

Entities:  

Mesh:

Year:  2002        PMID: 12063010

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  20 in total

1.  Unilateral neck therapy in the human papillomavirus ERA: accepted regional spread patterns.

Authors:  Thomas J Galloway; Miriam N Lango; Barbara Burtness; Ranee Mehra; Karen Ruth; John A Ridge
Journal:  Head Neck       Date:  2012-02-02       Impact factor: 3.147

2.  Parotid gland-recovery after radiotherapy in the head and neck region--36 months follow-up of a prospective clinical study.

Authors:  Jeremias Hey; Juergen Setz; Reinhard Gerlach; Martin Janich; Guido Hildebrandt; Dirk Vordermark; Christian R Gernhardt; Thomas Kuhnt
Journal:  Radiat Oncol       Date:  2011-09-27       Impact factor: 3.481

Review 3.  The standardization of acupuncture treatment for radiation-induced xerostomia: A literature review.

Authors:  Ling-Xin Li; Guang Tian; Jing He
Journal:  Chin J Integr Med       Date:  2015-08-26       Impact factor: 1.978

Review 4.  Radiotherapy dose-volume effects on salivary gland function.

Authors:  Joseph O Deasy; Vitali Moiseenko; Lawrence Marks; K S Clifford Chao; Jiho Nam; Avraham Eisbruch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

5.  The impact of dose on parotid salivary recovery in head and neck cancer patients treated with radiation therapy.

Authors:  Yun Li; Jeremy M G Taylor; Randall K Ten Haken; Avraham Eisbruch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-12-04       Impact factor: 7.038

Review 6.  Organ-sparing radiation therapy for head and neck cancer.

Authors:  XiaoShen Wang; ChaoSu Hu; Avraham Eisbruch
Journal:  Nat Rev Clin Oncol       Date:  2011-07-26       Impact factor: 66.675

7.  Can xerostomia be further reduced by sparing parotid stem cells?

Authors:  Avraham Eisbruch
Journal:  Ann Transl Med       Date:  2016-10

8.  Intensity-modulated radiotherapy vs. parotid-sparing 3D conformal radiotherapy. Effect on outcome and toxicity in locally advanced head and neck cancer.

Authors:  M Lambrecht; D Nevens; S Nuyts
Journal:  Strahlenther Onkol       Date:  2013-01-16       Impact factor: 3.621

Review 9.  A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life.

Authors:  S B Jensen; A M L Pedersen; A Vissink; E Andersen; C G Brown; A N Davies; J Dutilh; J S Fulton; L Jankovic; N N F Lopes; A L S Mello; L V Muniz; C A Murdoch-Kinch; R G Nair; J J Napeñas; A Nogueira-Rodrigues; D Saunders; B Stirling; I von Bültzingslöwen; D S Weikel; L S Elting; F K L Spijkervet; M T Brennan
Journal:  Support Care Cancer       Date:  2010-03-17       Impact factor: 3.603

10.  Unilateral and bilateral neck SIB for head and neck cancer patients : Intensity-modulated proton therapy, tomotherapy, and RapidArc.

Authors:  Carmen Stromberger; Luca Cozzi; Volker Budach; Antonella Fogliata; Pirus Ghadjar; Waldemar Wlodarczyk; Basil Jamil; Jan D Raguse; Arne Böttcher; Simone Marnitz
Journal:  Strahlenther Onkol       Date:  2016-02-06       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.